Calcium Channel Blockers Intake and Psoriasis: A Case-control Study

ARNON D. COHEN, MARK KAGEN, MICHAEL FRIGER and SIMA HALEVY

1Department of Dermatology and 2Department of Epidemiology and Health Services Evaluation, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

In vitro evidence suggests that intracellular calcium metabolism influences keratinocyte differentiation. However, only a few reports have described exacerbation of psoriasis or psoriasiform eruptions due to intake of calcium channel blockers. We conducted a case-control study to evaluate the association between exposure to calcium channel blockers and psoriasis. Data were obtained through a retrospective assessment of the files of 150 patients hospitalized for psoriasis or psoriasiform eruptions and 150 matched control patients. Exposure to calcium channel blockers was recorded in case and control patients. It was found that 13/150 patients hospitalized for psoriasis consumed calcium channel blockers. Calcium channel blockers were associated with precipitation of new-onset psoriasis (n = 2), as well as with the exacerbation of psoriasis (n = 11). The calcium channel blockers were as follows: nifedipine (n = 10), felodipine (n = 2) and amiodipine (n = 1). The median latent period between the beginning of intake of calcium channel blockers and precipitation or exacerbation of psoriasis was 28 months (range 4–143 months). A stepwise multivariate logistic regression analysis demonstrated that intake of calcium channel blockers was significantly associated with psoriasis, as compared to the control group (p = 0.018). Our study implies a possible role of calcium channel blockers as precipitating or exacerbating factors in patients with psoriasis. Key words: psoriasis; calcium; channel blockers; beta blockers; drug reactions.

(Accepted September 3, 2001.)

Acta Derm Venereol 2001; 81: 347–349.

Arnon Cohen, Department of Dermatology, Soroka University Medical Center, Beer-Sheva, 84101, Israel.

E-mail: arcohen@bgumail.bgu.ac.il

Drugs known to influence the onset or course of psoriasis are lithium, anti-malarial agents, anti-inflammatory drugs and beta-blockers. Angiotensin-converting enzyme inhibitors and miscellaneous agents have also been associated with psoriasis (1–11). Drugs may act by precipitation of new-onset psoriasis, in one of its defined forms, as a psoriasis-like (psoriasiform) eruption or by exacerbation of pre-existing psoriasis.

In vitro evidence suggests that calcium metabolism is important in the differentiation of keratinocytes and may be involved in the pathogenesis of psoriasis (12, 13). A literature search revealed only two reports of psoriasiform eruptions associated with intake of calcium channel blockers (14, 15).

We conducted a case-control study in order to evaluate the association between exposure to calcium channel blockers and precipitation or exacerbation of psoriasis.

PATIENTS AND METHODS

Patients

The study included 150 patients hospitalized for psoriasis or psoriasiform eruptions in the Department of Dermatology at the Soroka University Medical Center, between 5 May 1989 and 30 April 1999. Patients who were hospitalized more than once for psoriasis were included only at the first admission. Excluded from the study were patients for whom a diagnosis of psoriasis or psoriasiform eruption was not definite (e.g. patients with palmo-plantar pustulosis).

Inclusion criteria for the control group were determined in view of previous dermato-epidemiologic studies in psoriasis (16) and severe cutaneous drug reactions (17). Patients admitted to the same dermatology department in the same years, matched for age and sex, were selected as controls. Inclusion criteria for control patients were as follows: 1) acute dermatological diseases, unrelated to drug intake (e.g. acute contact dermatitis), 2) dermatological diseases unrelated to internal diseases, immunosuppression or immunosuppressive therapy (e.g. excluding patients with pemphigus vulgaris).

A total of 161 control patients were eligible for evaluation. After performing a review process, 11 controls were excluded from the study, leaving 150 control patients for the analysis. The admitting diagnoses of the control patients were as follows: 54 patients (36.1%) had acute contact dermatitis, 35 (23.3%) had skin infections (consisting mainly of cellulitis), 11 (7.3%) had insect bites, and 50 (33.3%) had miscellaneous conditions (consisting mainly of various forms of dermatitis or photodermatoses not related to drug intake). The characteristics of all patients are presented in Table I. Patients’ characteristics with respect to gender and age were similar in the case and control groups.

Methods

Data were collected retrospectively from the patients’ files, recording demographic and clinical characteristics, as well as data on the exposure to calcium channel blockers. Drug intake was recorded as indicated in the files, with no time limitation for assessment of drug exposure.

Determination of the index date

For case patients with new-onset psoriasis, the index day was defined as the first day of the appearance of rash. For case patients with exacerbated psoriasis, an index date was defined as a generalized spread of lesions in a patient with stable psoriasis or the appearance of erythroderma or of generalized pustular psoriasis. In the case of patients with psoriasiform eruptions, the index date was determined as the day of appearance of the rash. For control patients with chronic dermatoses, the index date was defined as the date of exacerbation of the disease leading to hospitalization. In control patients with acute dermatoses, the index date was defined as date of appearance of the dermatological disease.

Statistics

A statistical analysis was performed to compare intake of drugs by case and control patients, as previously described (17). Drugs were grouped on the basis of similar chemical structure or pharmacological
effect. Chi-square test or Fisher’s exact test were used as necessary. A stepwise multivariate logistic regression model was used for analysis. A calculation assuming a 10% exposure to calcium channel blockers in the case of patients and a 1% exposure to calcium channel blockers in controls showed that a target sample size of 121 cases and 121 controls would give an 80% chance to reject the null hypothesis at $p = 0.05$ level of significance.

RESULTS

Calcium channel blockers were taken by 13 patients (9 men and 4 women) in the case group compared to 3 patients in the control group. The mean age of these 13 patients was $64.1 \pm 8.9$ years. Patient and control characteristics are presented in Table I. Two patients had new-onset psoriasis and 11 patients had an exacerbation of pre-existing disease. Three patients had psoriatic arthritis and 10 patients had characteristic nail involvement. Three patients had palmo-plantar psoriasis and one patient had a positive family history of psoriasis.

The calcium channel blockers taken by the patients were as follows: nifedipine (10 patients), felodipine (2 patients) and amlodipine (1 patient) (Table II). The median latent period between the intake of calcium channel blockers and the precipitation or exacerbation of psoriasis was 28 months, ranging from 4 to 143 months. Seven patients took concomitantly beta-blockers (atenolol-5 patients, propranolol-1 patient, metoprolol-1 patient and a combination of propranolol and atenolol-1 patient).

A stepwise logistic regression analysis revealed that intake of calcium channel blockers was significantly associated with psoriasis ($p = 0.018$) (Table III).

DISCUSSION

In previous case reports and studies, efforts were made to identify drugs associated with psoriasis (1–11). In the current study, a case-control study was performed in order to estimate the role of exposure to calcium channel blockers in patients with psoriasis. A stepwise multivariate logistic regression analysis demonstrated that intake of calcium channel blockers was significantly associated with psoriasis, as compared to the control group ($p = 0.018$).

The use of calcium channel blockers was associated with precipitation of new-onset psoriasis as well as with exacerbation of psoriasis, but there was no association with psoriasis-form eruptions. Because of the small size of the study it was not possible to perform sub-group analyses according to the onset of psoriasis or sub-type of psoriasis.

In our study, we could not demonstrate a significant association between beta-blockers intake and psoriasis when using the multivariate model, which is contrary to previous observations (1, 2, 4–8). As 7/13 patients (53.8%) who took calcium channel blockers also took beta-blockers, it is possible that calcium channel blockers and beta blockers imposed a synergistic influence in our patients. However, our results may represent our patient population only, and should be repeated in additional cohorts in order to clarify possible complex interactions.

### Table I. Patients’ characteristics

| Case patients (n = 150) | Control patients (n = 150) |
|------------------------|---------------------------|
| Male/female (ratio)    | 94/56 (1.68)              | 94/56 (1.68) |
| Age (years)            | 45.1 ± 17.8               | 46.3 ± 17.9 |
| Mean ± SD              | Median (Range)            | 45 (13–88)   |
| Admitting diagnoses    |                           |             |
| Plaque-type psoriasis  | Acute contact dermatitis  |
| (n = 133)              | (n = 54)                  |
| Psoriasiform eruption  | Skin infections           |
| (n = 5)                | (n = 35)                  |
| Guttate psoriasis      | Insect and spider bites   |
| (n = 6)                | (n = 11)                  |
| Generalized pustular   | Miscellaneous             |
| psoriasis (n = 6)      | (n = 50)                  |

### Table II. Characteristics of 13 patients with psoriasis and intake of calcium channel blockers

| Patient no. | Age/sex | Effect on psoriasis | Calcium channel blockers intake | Latent period (months)* | Family history of psoriasis | Nail involvement | Psoriatic arthritis | Concomitant use of beta-blockers |
|-------------|---------|---------------------|--------------------------------|-------------------------|-----------------------------|------------------|---------------------|-----------------------------|
| 1           | 50/F    | Exacerbation        | Nifedipine                     | 12                      | –                           | +                | –                   | +                          |
| 2           | 50/M    | Exacerbation        | Nifedipine                     | 36                      | –                           | +                | –                   | +                          |
| 3           | 55/M    | Exacerbation        | Nifedipine                     | 7                       | –                           | +                | –                   | –                          |
| 4           | 58/M    | Exacerbation        | Nifedipine                     | 143                     | –                           | +                | +                   | –                          |
| 5           | 59/M    | Exacerbation        | Nifedipine                     | 84                      | –                           | +                | –                   | +                          |
| 6           | 63/M    | Exacerbation        | Amlodipine                     | 24                      | –                           | +                | –                   | –                          |
| 7           | 66/F    | New onset           | Nifedipine                     | 52                      | +                           | +                | –                   | –                          |
| 8           | 70/M    | Exacerbation        | Nifedipine                     | 34                      | –                           | –                | –                   | +                          |
| 9           | 70/F    | Exacerbation        | Felodipine                     | 13                      | –                           | +                | –                   | –                          |
| 10          | 70/M    | New onset           | Felodipine                     | 4                       | –                           | +                | –                   | +                          |
| 11          | 73/M    | Exacerbation        | Nifedipine                     | 20                      | –                           | –                | –                   | +                          |
| 12          | 73/M    | Exacerbation        | Nifedipine                     | 32                      | –                           | +                | –                   | –                          |
| 13          | 76/M    | Exacerbation        | Nifedipine                     | Unknown                 | –                           | +                | –                   | +                          |

*Latent period was defined as the time lag between the beginning of intake of a drug and the appearance of psoriasis de-novo or exacerbation of psoriasis (for definition of exacerbation of psoriasis, see text).
Calcium channel blockers intake and psoriasis

Table III. Stepwise multivariate model for cardiovascular drugs suspected of being associated with psoriasis vulgaris

| Drug                          | Case patients (n = 150) | Controls (n = 150) | Crude p-values | Multivariate p-values | Multivariate odds ratios (95% confidence intervals) |
|-------------------------------|-------------------------|--------------------|----------------|-----------------------|---------------------------------------------------|
| Calcium channel blockers      | 13 (8.7%)               | 3 (2%)             | 0.02           | 0.018                 | 3.5 (1.3–16.6)                                    |
| Beta-blockers                 | 12 (8%)                 | 3 (2%)             | 0.034          | Not in model          | –                                                 |
| ACE inhibitors                | 9 (6%)                  | 6 (4%)             | 0.43           | Not in model          | –                                                 |

ACE = Angiotensin converting enzyme.

associations between psoriasis and intake of beta blockers or calcium channel blockers.

The latent period between the intake of calcium channel blockers and precipitation or exacerbation of psoriasis was long (median duration: 28 months). This protracted latency is similar to the long latent period between the beginning of intake of beta-blockers and the precipitation or exacerbation of psoriasis, estimated as 1–3 years (1, 2, 4–7). No explanation has been suggested for the long latent period.

Only 1/13 patients (7.7%) who took a calcium channel blocker had a positive family history of psoriasis, as compared to 26/137 (19.0%) patients who did not take calcium channel blockers in the study. We may therefore presume that calcium channel blockers can exert their influence on psoriasis, regardless of a genetic background.

The possible influence of calcium channel blockers on psoriasis may ensue from their effect on keratinocyte differentiation, which is dependent on intracellular calcium levels (12). Derangement in calcium metabolism has been suggested as a possible mechanism for the influence of beta-blockers on psoriasis (18–20). This may also imply an effect of calcium channel blockers on psoriasis. A recent study has demonstrated that calcium influx, which is needed in the processing of profilaggrin to filaggrin, a final event in the cornification of epidermal cells, was inhibited by the calcium channel blocker nifedipine (13).

The current study was designed to test the potential impact of calcium channel blockers on psoriasis. Although our results are supported by in vitro evidence (12, 13), we suggest that a further large-scale dermato-epidemiologic study, using analytic epidemiologic methods, is needed to elucidate the relationship between intake of calcium channel blockers, beta-blockers or other drugs and the precipitation or exacerbation of psoriasis.

REFERENCES

1. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007–1022.
2. Gold MH, Holy AK, Roenigk HHJ. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19: 837–841.
3. Edwards BD, Chalmers RJ, O'Driscoll J, Lawson RS, Testa HJ, Ballardie FW. Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low-dose cyclosporin. Nephrol Dial Transplant 1993; 8: 1071–1078.
4. Assen ES, Banks RA. Practolol-induced drug eruption. Proc R Soc Med 1973; 66: 179–181.
5. Halevy S, Feuerman EJ. Psoriasiform eruption induced by propranolol. Cutis 1979; 24: 95–98.
6. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol – the role of an immunological mechanism. Arch Dermatol Res 1991; 283: 472–473.
7. Halevy S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol 1993; 29: 504–505.
8. Wolf R. A new concept in the pathogenesis of drug-induced psoriasis. Med Hypotheses 1986; 21: 277–279.
9. Tamir A, Wolf R, Brenner S. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1994; 30: 1045.
10. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 1990; 181: 51–53.
11. Gupta AK, Sibbald RG, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36: 858–862.
12. Mauro T, Dixon DB, Komuvles L, Hanley K, Pappone P. Keratinocyte K+ channels mediate Ca2+ -induced differentiation. J Invest Dermatol 1997; 108: 864–870.
13. Resing KA, al Alawi N, Blomquist C, Fleckman P, Dale BA. Independent regulation of two cytoplasmic processing stages of the intermediate filament-associated protein filaggrin and role of Ca2+ in the second stage. J Biol Chem 1993; 268: 25139–25145.
14. Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikekawa Z. Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. J Dermatol 1993; 20: 279–286.
15. Lavrijsen AP, Van Dijke C, Vermeer BJ. Diltiazem-associated exfoliative dermatitis in a patient with psoriasis. Acta Derm Venereol 1986; 66: 536–538.
16. Naldi L, Tognoni G, Cainelli T. Analytic epidemiology in psoriasis. J Invest Dermatol 1994; 102: 19S–23S.
17. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–1607.
18. Steinkraus V, Steinfath M, Mensing H. Beta-adrenergic blocking drugs and psoriasis. J Am Acad Dermatol 1992; 27: 266–267.
19. Steinkraus V, Mensing H. Psoriasis und beta-blockade. Hautarzt 1992; 43: 179–183.
20. Steinkraus V, Steinfath M, Korner C, Mensing H. Binding of beta-adrenergic receptors in human skin. J Invest Dermatol 1992; 98: 475–480.